Clinical Trial Update: Evaluation of Safety, Tolerability, and Changes in Biomarker and Clinical Outcome Assessments of Losmapimod for FSHD1 With Extension [Phase 2]

View source ↗

Summary

A Phase 2 study of losmapimod for facioscapulohumeral muscular dystrophy type 1 was terminated; the sponsor has posted results outlining safety, tolerability, b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Facioscapulohumeral Muscular Dystrophy Type

Drugs mentioned

• Losmapimod (losmapimod)

Snippet

Sponsor: Fulcrum Therapeutics | Conditions: Facioscapulohumeral Muscular Dystrophy 1 | Phase 2 | Status: TERMINATED | Results posted: 2025-12-02